• 不 限
  • 期刊论文
  • 硕博论文
  • 会议论文
  • 报 纸
  • 英文论文
  2. 您的位置
  3. 首页
  4. 会议论文
  5. Application of Physiologically Based Pharmacokinetic Modeling in Apatinib Clinical Pharmacokinetic S

Application of Physiologically Based Pharmacokinetic Modeling in Apatinib Clinical Pharmacokinetic S

来源 :第五届定量药理学与新药评价国际会议 | 被引量 : 0次 | 上传用户：abcd432110000
【摘 要】
：
Outlines · Introduction · In vitro ADME Properties · PBPK Modeling · Clinical PK of Apatinib in Healthy Volunteers · Prediction of Food Effect on Apatinib PK and DDIs using PBPK Model Introduction · A
【作 者】
：
Zhiwei Gao 
【机 构】
：
Center for DMPK Research Shanghai Institute of Materia Medica Chinese Academy of Sciences
【出 处】
：
第五届定量药理学与新药评价国际会议
【发表日期】
：
2015年4期
下载到本地 , 更方便阅读
下载此文 赞助VIP
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
Outlines · Introduction · In vitro ADME Properties · PBPK Modeling · Clinical PK of Apatinib in Healthy Volunteers · Prediction of Food Effect on Apatinib PK and DDIs using PBPK Model Introduction · A novel small molecule tyrosine kinase inhibitor targeting VEGFR-2.
其他文献
Combining “Bottom-up” and “Top-down” methods to assess ethnic difference in clearance of bitopertin
Background and objectives: Bitopertin (RG1678, RO4917838) is a glycine reuptake inhibitor that is postulated to improve NMDA receptor hypofunction by increasing the synaptic concentration of glycine,
会议
An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for suniti
Background: Breast cancer is one of the leading causes of mortality among women worldwide.As a potent multi-targeted receptor tyrosine kinase inhibitor, sunitinib has shown promising results in clinic
会议
A novel pharmacokinetic model based on the complex elimination of monoclonal antibodies for bevacizu
Background and Purpose: The complex pharmacokinetic (PK) properties of monoclonal antibody (mAb) including a nonlinear pharmacokinetics and a significant individual variation in PK process can not be
会议
BevacizumabModel fittingMonoclonal antibodyNonlinear eliminationPharmacokine
Population Pharmacokinetics of Vancomycin in Septicemia Infants and Its Application in Individualize
Objective: The objective of this study is to develop population pharmacokinetics model of vancomycin in treatment of septicemia in infants under one year old, to investigate factors which have signifi
会议
Infant septicemiaVancomycinPopulation pharmacokineticMonte CarloIndividualiz
Application of population pharmacokinetic modeling in clinical development of a novel PPI CPRCX: com
CPRCX is a novel investigated proton pump inhibitor, which shows dramatic success in the management of acid-related disorders.Now this drug is being developed in Phase Ⅱ study in China.In this paper f
会议
Pharmacokinetic-pharmacodynamic modeling of the anti-tumor tumor effect of sunitinib combined with d
Background: Lung cancer is the most lethal form of cancer in the world.Sunitinib is a promising multi-targeted receptor tyrosine kinase (RTK) inhibitor with activity against vascular endothelial growt
会议
The recent trend of population analysis for pediatric using allometric scaling and physiological sca
The pharmacokinetic(PK) of drugs and its parameters are different among pediatrics, children and adults due to physiological differences such as body size, maturation of organs.Since population pharma
会议
Pediatric population modelingAllometric scalingPhysiological scaling
Population pharmacokinetic pharmacodynamics model for PEGylated human growth hormone in healthy subj
Background: Growth hormone deficiency (GHD) in paediatric and adult patients so currently necessitates long-term treatment and persistence with a daily s.c injection regimen.Taking the low compliance
会议
Pharmacokinetic/Pharmacodynamic Modeling: Effect of Ibutilide on the QTcF Interval in Healthy Male S
Background: Ibutilide, a class Ⅲ antiarrhythmic agent, is primarily used for conversion of atrial flutter and fibrillation and is a good alternative to electrical cardioversion.However, ibutilide incr
会议
pharmacokineticibutilideEmax model
Selecting the target dose for phase Ⅱ clinical test of new drug using population approach of pre-cli
Introduction and purpose: Influenza viruses can show resistance to anti-viral drugs.This can result from over-use of these drugs and also due to the ability of influenza virus to mutate rapidly.For th
会议
Influenza virusphase Ⅱ clinical trialNONMEMsimulationWinNolin